Connect with us

coronavirus

European Commission reaches agreement to accelerate delivery of BioNTech/Pfizer vaccine

SHARE:

Published

5 years ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The Commission and BioNTech-Pfizer have come to an agreement on the accelerated delivery of 10 million doses for Quarter 2.

Commission President Ursula von der Leyen said: “I know how critical Quarter 2 is for the roll-out of our vaccination strategies in the member states. These accelerated 10 million doses will bring the total doses of BioNTech-Pfizer in Quarter 2 up to over 200 million. This is very good news. It gives member states room to manoeuvre and possibly fill gaps in deliveries.”

These doses would be drawn forward from the option of 100 million doses in the second BioNTech-Pfizer contract, foreseen for Q3 and Q4 of 2021. Today's (16 March) proposal by the Commission needs to be approved by the member states in the joint Steering Board.

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending